目的 分析肺腺癌中EZH2蛋白的表达,寻找更有效的肺腺癌治疗方法和为降低表皮生长因子受体酪氨酸激酶抑制药(epidermal growth factor receptor-tyrosine kinase inhibitors,EGFR-TKIs)耐药性提供理论依据。方法 免疫组织化学染色方法检测肺组织中EZH2蛋白表达情况,实时荧光PCR法检测肺腺癌EGFR基因突变状况。比较EZH2蛋白在腺癌、正常肺组织和肺良性病变组织中的表达差异,分析EZH2的表达与EGFR基因突变的相关性。结果 EZH2在腺癌组织中的表达率(84.00%)明显高于正常肺组织(12.00%)和肺良性病变组织(11.11%),差异均有统计学意义(P<0.05)。腺癌中EZH2的表达程度与患者的性别、年龄无关;与肿瘤的大小,组织学亚型及T分期有关(P<0.05);与EGFR基因突变无关。结论 EZH2可能参与肺腺癌的发生发展,其表达与EGFR基因突变无关,有可能成为肺腺癌治疗的新靶点。
Abstract
Objective To explore the expression of EZH2 in lung adenocarcinoma and its associations with EGFR mutation.Methods Immunohistochemistry was used to examine the expression of EZH2 while EGFR mutation was detected with real-time fluorescence PCR.Results The expression of EZH2 in lung adenocarcinom(84.00%) was significantly higher than in normal lung tissues(12.00%) and in benign lung disease(11.11%) (P<0.05). EZH2 expression was related to tumor size, histological subtypes of adenocarcinoma and T stage(P<0.05), but not to EGFR mutation.Conclusion EZH2 may be involved in lung oncogenesis and development. The expression of EZH2 is not linked to EGFR mutation. It can be a new target for the treatment of lung adenocarcinoma.
关键词
肺腺癌 /
EZH2 /
EGFR突变
Key words
lung adenocarcinoma /
EZH2 /
EGFR mutation
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Siegel R, Ma J, Zou Z, et al. Cancer statistics[J]. CA Cancer J Clin,2014,64(1):9-29.
[2] Mok T S, Wu Y L, Thongprasert S, et al. Gefitinib or carboplatin paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361(10):947-957
[3] Cao R, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3[J]. Curr Opin Cenet Dev,2004,14(2):155-164.
[4] Kondo Y, Shen L, Cheng A S, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation[J]. Nat Genet, 2008,40(6):741-750.
[5] Liu H H, Wang M Z, Hu K, et al. Research progress of the resistance mechanism of non-small cell lung cancer[J]. Chin J Lung Cancer, 2013,16(10):535-540
[6] Takawa M, Masuda K. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker[J]. Cancer sci, 2011, 102(7):1298-1305.
[7] Kikuchi J, Kinoshita I. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in non small cell lung cancers and their clinical and clinicopathologic significance[J]. Cancer, 2010, 116(12):3015-3024.
[8] Hu Q, Ishikawa R. Enhancer of zeste homolog 2 is a novel prognostic biomarker in non small cell lung cancer[J]. Cancer, 2012, 118(6):1599-1606.
[9] Wan L, Li X. Quantitative analysis of EZH2 expression and its correlations with lung cancer patients’ clinical pathological characteristics[J]. Clin Transl Oncol, 2013, 15(2):132-138.
[10] Lv Y, Yuan C. The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma[J]. Oncol Rep, 2012, 28(1):147-154.
[11] Behrens C, Solis L M. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma[J]. Clin Cancer Res, 2013,19(23):6556-6565.
[12] Takawa M, Masuda K. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker[J]. Cancer Sci, 2011, 102(7):1298-1305.
[13] Zhang J L, Su X L, Yan M R,et al . The effect of cell proliferation and migration by short hairpin RNA interference EZH2 expression in human lung cancer cell line[J]. Chen J Clinicians, 2011, 5(20):5871-5874.
[14] Zhang J G, Guo J F. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2[J]. J thoracic Oncol,2011,6(4):671-178.
[15] Xia H, Yu C H. EZH2 silencing with RNi enhances irradiation-induced inhibition of human lung cancer growth in vitro and in vivo[J]. Oncol lett, 2012, 4(1):135-140.
[16] Fillmore C M, Xu C. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors[J]. Nature, 2015, 520(7546):239-242.
基金
吉林省直卫生专项项目(编号:3D5153523429)
PDF(5192 KB)
